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Abstract 
 
Background/Aim. In vitro and in vivo studies show that 
CX3CL1 and CXCL16 chemokines and their specific recep-
tors, CX3CR1 and CXCR6, respectively, mediate mecha-
nism of neuroinflammation during the pathogenesis of mul-
tiple sclerosis (MS). The aim of this study was to investigate 
relative messenger ribonucleic acid (mRNA) levels of 
CX3CL1, CXCL16, CX3CR1 and CXCR6 in peripheral 
blood mononuclear cells, as potential molecular markers of 
relapsing-remitting (RR) MS. Methods. The study included 
43 unrelated RR MS patients, 20 of them with clinically ac-
tive disease (relapse) and 23 with clinically stable disease 
(remission), and 28 unrelated healthy subjects as controls. 
Real-time polymerase chain reactions (PCR) were per-
formed using TaqMan® gene expression assays. Relative ex-
pression (mRNA) level of each target gene in each sample 
of peripheral blood mononuclear cells was calculated as the 
mean normalized expression. Results. The levels of 
CX3CR1 mRNA were significantly higher in clinically active 
RR MS patients compared to controls [fold change = 1.38, p 
(Mann-Whitney U test) = 0.009], and significantly lower in 
clinically stable vs active RR MS patients [fold change = -
1.43, p (t-test) = 0.03]. Stable RR MS patients had signifi-
cantly higher CXCL16 mRNA levels than controls [fold 
change = 1.33, p (Mann-Whitney U test) = 0.006]. A trend 
of increased CXCR6 gene expression was found in active 
RR MS patients compared to controls [fold change = 1.23, p 
(Mann-Whitney U test) = 0.08]. In either active or stable RR 
MS patients there were no significant correlations of the 
clinical parameters with expression levels of the target 
genes. Conclusion. The current results show that increased 
CX3CR1 mRNA levels in peripheral blood mononuclear 
cells could represent a proinflammatory molecular marker 
of clinically active RR MS. 
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Uvod/Cilj. Studije in vitro i in vivo pokazuju da hemokini 
CX3CL1 i CXCL16 i njihovi specifični receptori, CX3CR1 i 
CXCR6, posreduju u mehanizmu neuroinflamacije tokom 
patogeneze multiple skleroze (MS). Cilj studije bio je 
ispitivanje relativnih nivoa informacione ribonukleinske 
kiseline (iRNK) za CX3CL1, CXCL16, CX3CR1 i CXCR6 u 
mononuklearnim leukocitima periferne krvi, kao potencijal-
nim molekularnim markerima relapsno-remitentne (RR) 
MS. Metode. Studijom su bila obuhvćena 43 bolesnika sa 
RR MS, koji nisu bili u srodstvu, od kojih je 20 bilo u 
klinički aktivnoj fazi bolesti (relaps), a 23 u klinički stabilnoj 
fazi bolesti (remisija), dok su 28 zdravih ispitanika, koji nisu 
bili u srodstvu, bili kontrola. Za izvođenje lančanih reakcija 
polimeraze u realnom vremenu korišćeni su genski ekspre-
sioni eseji TaqMan®. Relativni nivo ekspresije svakog ciljnog 
gena (iRNK) u svakom uzorku mononuklearnih leukocita 
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periferne krvi bio je računat kao srednja normalizovana 
ekspresija. Rezultati. Nivoi CX3CR1 iRNK bili su značajno 
viši kod bolesnika u fazi relapsa u poređenju sa kontrolama 
[“fold change” = 1,38, p (Mann-Whitney U test) = 0,009] i 
značajno niži kod bolesnika u fazi remisije u poređenju sa 
bolesnicima u relapsu [“fold change” = -1,43, p (t-test) = 0,03]. 
Bolesnici u remisiji su imali značajno više nivoe CXCL16 
iRNK nego kontrole [“fold change” = 1,33, p (Mann-Whitney 
U test) = 0,006]. Trend povećanja nivoa ekspresije CXCR6 
gena je bio nađen kod bolesnika u relapsu u poređenju sa 
kontrolama [“fold change” = 1,23, p (Mann-Whitney U test) 
= 0,08]. Ni kod jednog bolesnika, ni u fazi relapsa ni u fazi 
remisije, nije bilo značajnih korelacija između vrednosti 
kliničkih parametara i nivooa ekspresije ciljnih gena. 
Zaključak. Rezultati pokazuju da povećanje nivoa CX3CR1 
iRNK u mononuklearnim leukocitima periferne krvi može 
predstavljati proinflamatorni molekularni marker relapsa, tj. 
klinički aktivne faze relapsno-remitentne MS. 
 
Ključne reči: 
krv; hemokini; bolest, progresija; geni, ekspresija; 
leukociti; multipla skleroza; rnk, informativna. 
 
Introduction 
Chemokines are a family of cytokines, representing 
small soluble proteins that have an essential role in the 
stimulation of cell migration and intercellular communica-
tion 1. Changes in expression of certain chemokines and 
chemokine receptors in the central nervous system (CNS) 
can be associated with the pathogenesis of chronic neuroin-
flammatory and autoimmune diseases, such as multiple scle-
rosis (MS) 2. 
Both CX3CL1 (fractalkine) and CXCL16 chemokines 
are expressed in vascular endothelial cells 3, while CXCL16 
is also produced by monocytes/macrophages 4, B cells 5 and 
T cells 6. Specific receptors for these two chemokines, 
CX3CR1 and CXCR6, respectively, are expressed on the 
surface of leukocytes, T cells 7, 8, monocytes/macropha-
ges 9, 10 and non-killer (NK) cells 7, 8. CX3CL1 and CXCL16 
represent structurally and functionally unique chemokines. 
Each can exist as a soluble or a membrane-bound molecule 
and so can act as either a soluble chemoattractant or a mem-
brane adhesion molecule, regulating both leukocyte migra-
tion and leukocyte adhesion to the vascular wall, which are 
key events in the inflammatory process 5, 11. Conversion of 
the transmembrane into the soluble form of these two che-
mokines is achieved through regulated proteolysis of their 
transmembrane forms, by ADAM10 and ADAM17 extracel-
lular metalloproteinases 12. 
CX3CL1 and CX3CR1 are constitutively expressed in 
the CNS − CX3CL1 predominantly in neurons and CX3CR1 
in microglia, so they are important for the formation of inter-
cellular connections between neurons and microglial cells 1. 
Inducible CX3CL1 expression was detected in astrocytes of 
the CNS inflammatory lesions in experimental autoimmune 
encephalomyelitis (EAE) 13, while elevated levels of soluble 
CX3CL1 were measured in the cerebrospinal fluid and serum 
of MS patients 14, 15. CX3CL1 significantly increased the 
gene expression of proinflammatory cytokines in CD4+ T 
cells derived from patients with relapsing-remitting (RR) 
MS 14. In the inflammatory brain lesions of rats and mice 
with EAE, there was accumulation of microglial cells and 
peripheral leukocytes expressing CX3CR1 messenger ribo-
nucleic acid (mRNA), and CX3CR1 was responsible for the 
selective recruitment of NK cells into the CNS of these ani-
mals 13, 16. A significantly higher percentage of CD4+ 
CX3CR1+ T cells was detected in blood of RR MS patients 
compared to healthy controls 14, and CX3CR1 mediated the 
recruitment of cytotoxic T cells into the brain tissue of pa-
tients with MS 17. In normal CNS tissue, CXCL16 expression 
is low and mostly restricted to endothelial cells 18. However, 
production of CXCL16 in the CNS has been increased dur-
ing both preclinical and acute EAE 19. It was found that 
CXCL16 could act as a proinflammatory chemokine in the 
pathogenesis of MS because, in animals with EAE, applica-
tion of CXCL16 monoclonal antibodies resulted in: reduced 
disease incidence, decreased infiltration of mononuclear leu-
kocytes into the CNS, decreased level of serum interferon 
gamma (IFNγ) and decreased production of myelin-specific 
T cells 20. The levels of soluble CXCL16 in the human serum 
and cerebrospinal fluid were significantly increased in MS 
and other neuroinflammatory autoimmune diseases 21. Ex-
pression of CXCR6 was typically detected in myelin-reactive 
IFNγ-producing CD4+ Th1 cells of EAE mice 20. Also, 
CXCR6 was upregulated in neutrophils, which accumulated 
in the brain prior to and during the acute EAE attacks 19. 
In vitro and in vivo studies indicate that CX3CL1 and 
CXCL16 chemokines and their specific receptors, CX3CR1 
and CXCR6, respectively, are involved in the mechanism of 
neuroinflammation during the pathogenesis of MS. We had 
previously shown association of the single nucleotide vari-
ants in CXCL16 and CX3CR1 genes with susceptibility and 
progression of MS 22, 23. The aim of the current study was to 
investigate changes in relative gene expression of CX3CL1 
and CXCL16 chemokines and their receptors at mRNA lev-
els in peripheral blood mononuclear cells (PBMC), as poten-
tial molecular markers of RR MS. 
Methods 
Subjects 
The study included 43 unrelated patients with MS, from 
the Clinic for Neurology of the Military Medical Academy 
(MMA), Belgrade, Serbia. All patients were diagnosed with 
clinically definite MS 24 and the clinical course of the disease 
was defined 25. For estimation of the disease severity, the 
Expanded Disability Status Scale 26 and the Multiple Sclero-
sis Severity Score 27 parameters were calculated, according 
to clinical data obtained at the time when blood specimens 
for genetic analysis were collected. Of 43 patients, 20 had 
clinically active RR MS (relapse) and 23 had clinically stable 
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RR MS (remission). Patients with stable RR MS were treated 
with 0.25 mg of interferon beta-1b (Betaferon®, Bayer 
Pharma AG), every other day, over a period of at least 12 
months. The control group consisted of 28 unrelated healthy 
volunteers of the Military MMA personnel. Both controls and 
patients were of Serbian ethnic origin. The Ethics Committee 
of the MMA approved the study, and each participant gave 
his/her written informed consent to participate in the study. 
Real-time reverse transcription-quantitative polymerase 
chain reaction (PCR) and calculation of relative gene 
expression (mRNA) levels of CX3CL1, CXCL16, 
CX3CR1 and CXCR6 
Fresh blood samples (3 mL) were used for separation of 
PBMC, with lymphocyte separation medium (PAA, GE 
Healthcare), and extraction of PBMC total RNA, with TRI 
Reagent (Ambion, Life Technologies). The quality and quan-
tity of total RNA were assessed using RNA 6,000 Nano Kit, 
on 2,100 Bioanalyzer (Agilent, US). 
Each PBMC sample total RNA (500 ng) was treated 
with DNAseI (Fermentas, Thermo Fisher Scientific) and the 
reverse transcription was done using First strand cDNA syn-
thesis kit, with oligo-dT18 and random hexamer primers 
(Fermentas, Thermo Fisher Scientific), in a reaction volume 
of 20 µL. Real-time polymerase chain reactions (PCR) were 
performed on Applied Biosystems 7500 Real-Time PCR sys-
tem, by use of the following TaqMan® gene expression as-
says: Hs00171086_m1 (for CX3CL1), Hs01055223_g1 (for 
CXCL16), Hs01922583_s1 (for CX3CR1), Hs01890898_s1 
(for CXCR6), Hs99999905_m1 (for GAPDH), 
Hs99999904_m1 (for PPIA) and Hs99999901_s1 (for 18S 
rRNA). Each real-time PCR reaction contained 1 µL of the 
reverse transcription product, in a total reaction volume of 13 
µL. All samples were run in duplicates. 
NormFinder algorithm 28 was used for identification of 
the optimal endogenous control among the candidate genes 
(GAPDH, peptiddylprolylcis-trans-isomerase A PPIA and 
18S rRNA), according to their expression stability in a given 
sample group and a given study design. Based on the input 
data, representing Ct values were transformed to linear scale 
expression quantities by delta-Ct method. NormFinder calcu-
lated the stability value for each candidate gene, which was a 
direct measure of the estimated gene expression variation. 
The relative expression level of each target gene in each 
PBMC sample was calculated as the mean normalized ex-
pression (MNE), according to the following formula 29: MNE 
= (Ereference)Ct reference, mean / (Etarget)Ct target, mean, where E repre-
sented PCR amplification efficiency for the reference (en-
dogenous control) gene (Ereference) and the target gene (Etarget), 
and Ct represented an average cycle threshold value from the 
two replicates, for the reference gene (Ct reference, mean) 
and for the target gene (Ct target, mean). TaqMan® gene ex-
pression assays provide the amplification efficiency of 
100%, meaning that Ereference = Etarget = 2, so the above for-
mula for calculating the relative expression level of each tar-
get gene in each sample has become: MNE = 2 (Ct reference, mean - 
Ct target, mean), MNE = 2 - (Ct target, mean - Ct reference, mean) = 2 -dCt. For 
verifying the relative gene expression results, relative ex-
pression software tool REST 2009 was used 30. 
Statistical analysis 
The statistical analysis was performed using Statistica 
8.0 software package (StatSoft, Inc. 1984–2007). Compari-
sons of continuous variables between the tested sample 
groups were done by t-test and Analysis of Variance or by 
Mann-Whitney U test and Kruskal-Wallis test, depending on 
whether variable values had a normal or a non-normal distri-
bution. Correlations between continuous variables were 
tested by product-moment and partial correlations. In all sta-
tistical tests, p < 0.05 values were considered statistically 
significant. Graphs were designed using GraphPad Prism 
5.00 (GraphPad Software, San Diego California USA). 
Results 
Controls and RR MS patients 
Characteristics of controls and RR MS patients who 
participated in the study are shown in Table 1. There was no 
significant difference in age between controls, patients with 
clinically active and patients with clinically stable RR MS 
[Table 1; p (Kruskal-Wallis test) = 0.72]. In each of the three 
groups, female-to-male ratio was > 1 (Table 1). 
 
Table 1 
Characteristics of the study participants 
Parameter 
Controls 
(n = 28) 
Active RR MS patients 
(n = 20) 
Stable RR MS patients 
(n = 23) 
Age (years) 33.0 (25.0−64.0) # 32.5 ± 8.2 35.2 ± 7.5 
Gender (female/male) 21/7 16/4 12/11 
Disease onset age  (years) − 29.0 ± 7.9 27.5 ± 8.6 
Duration of disease (years) − 2.0 (1.0−15.0) # 6.0 (1.0−31.0) # 
Expanded disability status scale − 1.5 (1.0−3.5) # 2.0 (1.0−4.5) # 
MS severity score − 3.5 ± 1.9 4.0 ± 1.6 
Values of continual parameters with a normal distribution are presented as mean ± standard deviation; #values of continual 
parameters with a non-normal distribution are presented as median (minimum–maximum). 
MS – multiple sclerosis; RR – relapsing-remitting. 
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Relative expression (mRNA) levels of CX3CL1, 
CX3CR1, CXCL16 and CXCR6 genes in PBMC  
of controls and patients with RR MS 
In all tested PBMC samples, we detected the amplifica-
tion of each target gene’s mRNA (complementary DNA), 
except of CX3CL1 mRNA. By comparing the values of sta-
tistical parameter that represents the expression stability for 
each of the three tested endogenous control genes and by 
comparing the amplification profiles of endogenous control 
genes with amplification profiles of target genes, PPIA was 
found to be the optimal endogenous control for normalizing 
the results of expression of target genes in the analyzed 
PBMC samples. The statistical analysis of relative expres-
sion levels of the target genes in PBMC of controls and MS 
patients is presented in Figure 1 and Table 2. The levels of 
CX3CR1 mRNA were significantly higher in clinically ac-
tive RR MS patients compared to controls [fold change = 
1.38, p (Mann-Whitney U test) = 0.009], and significantly 
lower in clinically stable vs active RR MS patients [fold 
change = -1.43, p (t-test) = 0.03] (Figure 1 A, Table 2). Sta-
ble RR MS patients had significantly higher CXCL16 
mRNA levels than controls [fold change = 1.33, p (Mann-
Whitney U test) = 0.006] (Figure 1 B, Table 2). A trend of 
increased CXCR6 gene expression was found in active RR 
MS patients compared to controls [fold change = 1.23, p 




Statistical analysis of CX3CR1, CXCL16 and CXCR6 
relative gene expression (mRNA) levels in peripheral 




CX3CR1 relative gene expression    
active RR MS patients vs controls 1.38 0.009 **
stable vs active RR MS patients -1.43 0.03 * 
stable RR MS patients vs controls -1.03 0.66 
CXCL16 relative gene expression    
active RR MS patients vs controls 1.20 0.39 
stable vs active RR MS patients 1.11 0.20 
stable RR MS patients vs controls 1.33 0.006 ** 
CXCR6 relative gene expression    
active RR MS patients vs controls 1.23 0.08 
stable vs active RR MS patients -1.22 0.26 
stable RR MS patients vs controls 1.01 0.97 
RR MS – relapsing-remitting multiple sclerosis.  
Fold change – mean relative gene expression level (mean 2-dCt) 
of the target sample group to mean relative gene expression 
level of the reference sample group ratio (* – statistically 
significant difference when p < 0.05; ** – statistically 









Fig. 1 – Relative expression (mRNA) levels of the target 
genes in peripheral blood mononuclear cells. 
A) Relative expression of CX3CR1 gene; B) Relative 
expression of CXCL16 gene; C) Relative expression of 
CXCR6 gene. The analyzed groups are controls (n = 28), 
active relapsing-remitting multiple sclerosis (RR MS) 
patients (n = 20) and stable RR MS patients (n = 23). For 
each target gene, the expression levels are normalized to 
endogenous control gene peptidylprolyl cis-trans-isomerase 
A (PPIA) and shown for each analyzed sample group (graph 
bars) as mean relative gene expression level (mean 2-dCt) 
with its standard error (* – statistically significant difference 
when p < 0.05; ** – statistically significant difference when p 
< 0.01). 
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Correlations between levels of the target mRNAs in 
controls and patients with RR MS 
No significant correlations were established between 
CXCL16 and CXCR6 mRNA levels or between CX3CR1 
and CXCR6 mRNA levels, within each analyzed sample 
group – controls, active RR MS patients or stable RR MS pa-
tients (product-moment and partial correlations, p > 0.05). 
Correlations of clinical parameters with levels of the 
target mRNAs in patients with RR MS 
In either active or stable RR MS patients there were no 
significant correlations between values of clinical parameters 
(Expanded Disability Status Scale, Multiple Sclerosis Sever-
ity Score) and mRNA levels of CX3CR1, CXCL16 or 
CXCR6 in PBMC (product-moment and partial correlations, 
p > 0.05). 
Discussion 
Important purpose of research regarding the molecular 
basis of MS is to identify gene expression changes in the 
immune cells of peripheral blood, which may reflect the pa-
thological changes in the target CNS tissue. The aim of the 
present study was to analyze the relative gene expression of 
CX3CL1 and CXCL16 chemokines and their specific recep-
tors, CX3CR1 and CXCR6, respectively, at the mRNA lev-
els in PBMC samples of patients with RR MS and healthy 
control subjects. We found that changes in PBMC CX3CR1 
mRNA levels may represent a molecular marker of RR MS. 
A proposed proinflammatory role of CX3CL1 in the pa-
thogenesis of MS is supported by the fact that CX3CL1 sig-
nificantly increased the expression of IFNγ gene in CD4+ T 
cells and secretion of IFNγ from these cells, derived from 
RR MS patients but not healthy individuals 14. In rheumatoid 
arthritis, representing a T cell-mediated inflammatory and 
autoimmune disease, such as MS, CX3CL1 was expressed in 
T cells of patients. Yet, there was a low overall proportion of 
CX3CL1-expressing peripheral T cells in both rheumatoid 
arthritis patients and controls 31. Likewise, in the current 
study, expression of CX3CL1 mRNA was not detectable in 
PBMC of either MS patients or controls. On the other hand, 
inducible expression of CX3CL1 in endothelial cells, as well 
as CX3CL1 proteolytic cleavage from the surface of these 
cells, was demonstrated in vitro, in response to inflammatory 
mediators 32. This finding 32, along with ours, proposes that 
the inducible endothelial expression of CX3CL1 followed by 
its inducible proteolytic cleavage from the endothelial sur-
face represents the main cause of a significant increase in 
circulating soluble CX3CL1 levels, having been shown in 
patients with RR MS 14, 15. 
We detected significantly higher levels of PBMC 
CX3CR1 mRNA in patients with clinically active RR MS 
compared to both controls and patients with clinically stable 
RR MS. The study of relative gene expression, analyzed by 
real-time PCR, in PBMC samples of 28 healthy controls and 
25 patients with RR MS showed that the levels of CX3CR1 
mRNA, as well as percentage of CX3CR1+ cells, were sig-
nificantly lower in patients compared to controls 33. This de-
creased CX3CR1 gene expression in patients may be ex-
plained by the fact that most of them were clinically stable 33. 
Likewise, we found a significant decrease in CX3CR1 
mRNA levels in stable RR MS patients compared to the ac-
tive ones. Furthermore, in microarray analysis by Infante-
Duarte et al. 33, the only patient who suffered a relapse 14 
days after venipuncture had an increased CX3CR1 gene ex-
pression in comparison to healthy individuals, which is con-
sistent with our finding. Previous research indicated the pro-
inflammatory properties of peripheral CX3CR1+ CD4+ T 
cells and CX3CR1+ NK cells, by which these cells should 
contribute to the process of neuroinflammation in RR MS, 
especially during relapse 14, 17, 33. Accordingly, our finding 
suggests that the increase in PBMC CX3CR1 mRNA levels 
represents a potential proinflammatory molecular marker of 
active RR MS. 
Both CXCL16 chemokine and its receptor, CXCR6, 
are widely expressed in PBMC 4–6, 8, 20. CXCL16 from mo-
nocytes infiltrated in the CNS of EAE mice was suggested 
to induce chemotaxis and accumulation of activated mye-
lin-specific CXCR6+ CD4+ Th1 cells in the CNS tissue, 
indicating a proinflammatory action of CXCL16 in the pa-
thogenesis of EAE 20. Production of CXCL16 in the CNS 
was increased during the acute EAE 19, and severity of EAE 
positively correlated with CNS mRNA and protein levels of 
CXCL16 and CXCR6 20. The analysis of brain tissue from 
MS patients demonstrated an increase in CXCL16 expres-
sion by foamy macrophages in the rims of chronic active 
brain lesions 34. Considering the foregoing results obtained 
in vivo and in vitro, we expected to find out elevated 
CXCL16 and CXCR6 gene expression levels in PBMC of 
the patients. In clinically active RR MS patients compared 
to controls, we detected no significant differences in either 
CXCL16 or CXCR6 mRNA levels, although there was a 
trend of increased CXCR6 gene expression. CXCR6 was an 
indicator of IFNγ production, since the intracellular synthe-
sis of IFNγ significantly positively correlated with expres-
sion of CXCR6 on the surface of MBP-reactive CD4+ Th1 
cells 35. The trend that we found, along with this finding of 
Calabresi et al. 35, suggests further investigation in order to 
evaluate the hypothesised role of CXCR6 as a proinflam-
matory marker of RR MS, typically of the active phase of 
the disease. In the present analysis of PBMC CXCL16 gene 
expression, we detected significantly higher mRNA levels 
only in patients with stable RR MS in comparison to con-
trols. These patients were receiving interferon-beta treat-
ment, which is known to suppress the secretion of proin-
flammatory cytokines 36. An in vitro study showed no cor-
relation between CXCL16 expression and interferon-beta 
treatment 37. Considering the hypothesised proinflamma-
tory action of CXCL16 in the pathogenesis of MS 20, the 
largest increase in CXCL16 gene expression is expected to 
be found in clinically active RR MS patients. As the inten-
sity of inflammation and autoimmune response decreases 
during the stable phase of the disease, CXCL16 expression 
should also decrease. Yet, we did not find its decrease in 
Page 972 VOJNOSANITETSKI PREGLED Vol. 77, No 9 
Stojković Lj, et al. Vojnosanit Pregl 2020; 77(9): 967–973. 
stable RR MS. Therefore, the increased PBMC CXCL16 
mRNA levels in patients with clinically stable disease in 
the current study could be due to some pleiotropic effect(s) 
of CXCL16 on pathogenesis of RR MS, which is(are) not 
directly related to inflammation. 
We aware that our study has limitations. One is the re-
stricted inclusion of patients with clinically stable disease 
who are treatment-naïve. Thus, to create a homogenous 
group of clinically stable patients, we deliberately selected 
only those receiving interferon-beta treatments. We did not 
show which subpopulation(s) of PBMC underlay the de-
tected significant changes in gene expression, and this repre-
sents another limitation of the study. Still, the expression 
changes were detected in total PBMC, which represent a 
valid source of potential MS biomarkers quantified at the 
level of mRNA and/or protein 38–40. 
Conclusion 
The current study demonstrates that the increased 
CX3CR1 mRNA expression in PBMC could represent a pro-
inflammatory molecular marker of clinically active RR MS. 
The results should be verified in future studies with a larger 
number of samples. In addition, more functional research is 
needed to fully clarify the roles of CX3CL1, CXCL16, 
CX3CR1 and CXCR6 in the pathogenesis of MS. Despite 
limitations, the present study adds value to investigation of 
CX3CL1, CXCL16, CX3CR1 and CXCR6 gene expression 
in the immune cells of RR MS patients, with respect to the 
disease activity. 
Acknowledgement 
The study was funded by the Serbian Ministry of Edu-
cation, Science and Technological Development. 
 
R E F E R E N C E S
1. Le Thuc O, Blondeau N, Nahon JL, Rovère C. The complex con-
tribution of chemokines to neuroinflammation: switching 
from beneficial to detrimental effects. Ann N Y Acad Sci 
2015; 1351: 127−40. 
2. Réaux-Le Goazigo A, Van Steenwinckel J, Rostène W, Mélik Parsa-
daniantz S. Current status of chemokines in the adult CNS. 
Prog Neurobiol 2013; 104: 67−92. 
3. Chen T, Guo ZP, Jiao XY, Jia RZ, Zhang YH, Li JY, et al. Peo-
niflorin suppresses tumor necrosis factor-α induced chemo-
kine production in human dermal microvascular endothelial 
cells by blocking nuclear factor-κB and ERK pathway. Arch 
Dermatol Res 2011; 303(5): 351−60. 
4. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita 
T, et al. Molecular cloning of a novel scavenger receptor for 
oxidized low density lipoprotein, SR−PSOX, on macrophages. 
J Biol Chem 2000; 275(52): 40663−6. 
5. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P, et 
al. Expression cloning of the STRL33/BONZO/TYMSTR li-
gand reveals elements of CC, CXC, and CX3C chemokines. J 
Immunol 2001; 166: 5145−54. 
6. Shashkin P, Simpson D, Mishin V, Chesnutt B, Ley K. Expression 
of CXCL16 in human T cells. Arterioscler Thromb Vasc Biol 
2003; 23(1): 148−9. 
7. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, 
et al. Identification and molecular characterization of frac-
talkine receptor CX3CR1, which mediates both leukocyte mi-
gration and adhesion. Cell 1997; 91(4): 521−30. 
8. Wehr A, Baeck C, Heymann F, Niemietz PM, Hammerich L, Martin 
C, et al. Chemokine receptor CXCR6-dependent hepatic NK 
T Cell accumulation promotes inflammation and liver fibrosis. 
J Immunol 2013; 190(10): 5226−36. 
9. Rennert K, Heisig K, Groeger M, Wallert M, Funke H, Lorkowski S, 
et al. Recruitment of CD16(+) monocytes to endothelial cells 
in response to LPS-treatment and concomitant TNF release is 
regulated by CX3CR1 and interfered by soluble fractalkine. 
Cytokine 2016; 83: 41−52. 
10. Wang JH, Su F, Wang S, Lu XC, Zhang SH, Chen D, et al. 
CXCR6 deficiency attenuates pressure overload-induced mo-
nocytes migration and cardiac fibrosis through downregulating 
TNF-α-dependent MMP9 pathway. Int J Clin Exp Pathol 
2014; 7(10): 6514−23. 
11. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. 
A new class of membrane−bound chemokine with a CX3C 
motif. Nature 1997; 385(6617): 640‒4. 
12. Ludwig A, Weber C. Transmembrane chemokines: versatile 
‘special agents’ in vascular inflammation. Thromb Hae-
most 2007; 97(5): 694−703. 
13. Sunnemark D, Eltayeb S, Nilsson M, Wallstrom E, Lassmann H, 
Olsson T, et al. CX3CL1 (fractalkine) and CX3CR1 expression 
in myelin oligodendrocyte glycoprotein−induced experimental 
autoimmune encephalomyelitis: kinetics and cellular origin. J 
Neuroinflammation 2005; 2: 17. 
14. Blauth K, Zhang X, Chopra M, Rogan S, Markovic-Plese S. The role 
of fractalkine (CX3CL1) in regulation of CD4(+) cell migra-
tion to the central nervous system in patients with relaps-
ing−remitting multiple sclerosis. Clin Immunol 2015; 157(2): 
121−32. 
15. Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister 
HW. CSF and serum levels of soluble fractalkine (CX3CL1) in 
inflammatory diseases of the nervous system. J Neuroimmunol 
2003; 137(1‒2): 210−7. 
16. Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP, et 
al. The neuronal chemokine CX3CL1/fractalkine selectively 
recruits NK cells that modify experimental autoimmune en-
cephalomyelitis within the central nervous system. FASEB 
J 2006; 20(7): 896−905. 
17. Broux B, Pannemans K, Zhang X, Markovic−Plese S, Broekmans T, 
Eijnde BO, et al. CX(3)CR1 drives cytotoxic CD4(+)CD28(−) 
T cells into the brain of multiple sclerosis patients. J Autoim-
mun 2012; 38(1): 10−9. 
18. Ludwig A, Schulte A, Schnack C, Hundhausen C, Reiss K, Brodway 
N, et al. Enhanced expression and shedding of the transmem-
brane chemokine CXCL16 by reactive astrocytes and glioma 
cells. J Neurochem 2005; 93(5): 1293−303. 
19. Wojkowska DW, Szpakowski P, Ksiazek-Winiarek D, Leszczynski 
M, Glabinski A. Interactions between neutrophils, Th17 cells, 
and chemokines during the initiation of experimental model of 
multiple sclerosis. Mediators Inflamm 2014; 2014: 590409. 
20. Fukumoto N, Shimaoka T, Fujimura H, Sakoda S, Tanaka M, Kita 
T, et al. Critical roles of CXC chemokine ligand 16/scavenger 
receptor that binds phosphatidylserine and oxidized lipopro-
tein in the pathogenesis of both acute and adoptive transfer 
experimental autoimmune encephalomyelitis. J Immunol 2004; 
173(3): 1620−7. 
Vol. 77, No 9 VOJNOSANITETSKI PREGLED Page 973 
Stojković Lj, et al. Vojnosanit Pregl 2020; 77(9): 967–973. 
21. Le Blanc LM, van Lieshout AW, Adema GJ, van Riel PL, Verbeek 
MM, Radstake TR. CXCL16 is elevated in the cerebrospinal 
fluid versus serum and in inflammatory conditions with sus-
pected and proved central nervous system involvement. Neu-
rosci Lett 2006; 397(1‒2): 145−8. 
22. Stojković L, Stanković A, Djurić T, Dinčić E, Alavantić D, Zivković 
M. The gender-specific association of CXCL16 A181V gene 
polymorphism with susceptibility to multiple sclerosis, and its 
effects on PBMC mRNA and plasma soluble CXCL16 levels: 
preliminary findings. J Neurol 2014; 261(8): 1544−51. 
23. Stojković L, Djurić T, Stanković A, Dinčić E, Stančić O, Veljković 
N, et al. The association of V249I and T280M fractalkine re-
ceptor haplotypes with disease course of multiple sclerosis. J 
Neuroimmunol 2012; 245(1-2): 87−92. 
24. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi 
M, et al. Diagnostic criteria for multiple sclerosis: 2010 revi-
sions to the McDonald criteria. Ann Neurol 2011; 69(2): 
292−302. 
25. Lublin FD, Reingold SC. Defining the clinical course of multiple 
sclerosis: results of an international survey. National Multiple 
Sclerosis Society (USA) Advisory Committee on clinical trials 
of New Agents in Multiple Sclerosis. Neurol 1996; 46(4): 
907−11. 
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: 
an expanded disability status scale (EDSS). Neurol 1983; 
33(11): 1444−52. 
27. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, 
Vukusic S, et al. Multiple Sclerosis Severity Score: using disabil-
ity and disease duration to rate disease severity. Neurol 2005; 
64(7): 1144−51. 
28. Andersen CL, Jensen JL, Ørntoft TF. Normalization of real−time 
quantitative reverse transcription−PCR data: a model−based 
variance estimation approach to identify genes suited for nor-
malization, applied to bladder and colon cancer data sets. Can-
cer Res 2004; 64(15): 5245−50. 
29. Zimmermann AK, Simon P, Seeburger J, Hoffmann J, Ziemer G, Ae-
bert H, et al. Cytokine gene expression in monocytes of patients 
undergoing cardiopulmonary bypass surgery evaluated by 
real−time PCR. J Cell Mol Med 2003; 7(2): 146−56. 
30. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software 
tool (REST) for group−wise comparison and statistical analy-
sis of relative expression results in real−time PCR. Nucl Ac 
Res 2002; 30(9): e36. 
31. Blaschke S, Koziolek M, Schwarz A, Benöhr P, Middel P, Schwarz G, 
et al. Proinflammatory role of fractalkine (CX3CL1) in rheu-
matoid arthritis. J Rheumatol 2003; 30(9): 1918−27. 
32. Hurst LA, Bunning RA, Couraud PO, Romero IA, Weksler BB, 
Sharrack B, et al. Expression of ADAM−17, TIMP−3 and frac-
talkine in the human adult brain endothelial cell line, 
hCMEC/D3, following pro−inflammatory cytokine treatment. 
J Neuroimmunol 2009; 210(1‒2): 108−12. 
33. Infante-Duarte C, Weber A, Kratzschmar J, Prozorovski T, Pikol S, 
Hamann I, et al. Frequency of blood CX3CR1−positive natural 
killer cells correlates with disease activity in multiple sclerosis 
patients. FASEB J 2005; 19(13): 1902−4. 
34. Hendrickx DA, Koning N, Schuurman KG, van Strien ME, van 
Eden CG, Hamann J, et al. Selective upregulation of scavenger 
receptors in and around demyelinating areas in multiple sclero-
sis. J Neuropathol Exp Neurol 2013; 72(2): 106−18. 
35. Calabresi PA, Yun SH, Allie R, Whartenby KA. Chemokine re-
ceptor expression on MBP-reactive T cells: CXCR6 is a mark-
er of IFNgamma-producing effector cells. J Neuroimmunol 
2002; 127(1‒2): 96−105. 
36. Haji Abdolvahab M, Mofrad MR, Schellekens H. Interferon beta: 
from molecular level to therapeutic effects. Int Rev Cell Mol 
Biol 2016; 326: 343−72. 
37. Derbigny WA, Shobe LR, Kamran JC, Toomey KS, Ofner S. Identi-
fying a role for Toll−like receptor 3 in the innate immune re-
sponse to Chlamydia muridarum infection in murine oviduct 
epithelial cells. Infect Immun 2012; 80: 254−65. 
38. Tamtaji OR, Kouchaki E, Salami M, Aghadavod E, Akbari E, Ta-
jabadi-Ebrahimi M, et al. The effects of probiotic supplementa-
tion on gene expression related to inflammation, insulin, and 
lipids in patients with multiple sclerosis: a randomized, double-
blind, placebo-controlled trial. J Am Coll Nutr 2017; 36(8): 
660−5. 
39. Mindur JE, Valenzuela RM, Yadav SK, Boppana S, Dhib-Jalbut S, 
Ito K. IL-27: a potential biomarker for responders to glatiramer 
acetate therapy. J Neuroimmunol 2017; 304: 21−8. 
40. Ciriello J, Tatomir A, Hewes D, Boodhoo D, Anselmo F, Rus V, et 
al. Phosphorylated SIRT1 as a biomarker of relapse and re-
sponse to treatment with glatiramer acetate in multiple sclero-
sis. Exp Mol Pathol 2018; 105(2): 175−80. 
 
Received on July 17, 2018.  
Revised on December 3, 2018.  
Accepted March 11, 2019. 
Online First March, 2019. 
 
